Recipharm, a contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services.
Located in Israel, Hadasit, offers a variety of research, development and consulting services to customers, primarily in the Middle East. The company is a wholly owned subsidiary of Hadassah Medical Organisation (HMO).
With its unique access to HMO's expert clinicians and researchers, the company provides clinical-orientated R&D services that can assist customers from the point of early preclinical development up to regulatory approval, saving time and money.
Recipharm’s Israeli facility, established in 2015, has partnered with Hadasit to enable a more seamless customer experience as pharmaceutical products progress through clinical phases.
Dr Sylvia Kachalsky, Site Manager at Recipharm in Israel, said: “Developing a drug involves chemical, biological and clinical expertise. Our partnership with Hadasit means we can offer these services more efficiently and manage projects seamlessly from development to clinic.”
Dr Kachalsky continued: “The partnership will support business growth in Israel, giving Recipharm access to the majority of the clinical trials taking place in the country. While the field of chemistry services is relatively new to this market, the growth potential is substantial, with more than 800 biotech companies in Israel and the number and size of these companies continuing to grow.”
Hadasit brings a number of specialist services to the partnership, including in vitro analysis in various models, access to and analysis of human samples, in vivo models for multiple medical conditions, input regarding medical indications and the conducting of clinical trials at all phases.
Dr Tamar Raz, CEO at Hadasit said: “Through the partnership we will be able to offer a full service for the synthesis and testing of compounds. Working with Recipharm, our team will gain professional input regarding the compounds that Hadassah researchers and Hadasit companies are developing, including synthesis and medicinal chemistry challenges.”
“We are looking forward to a mutually beneficial long-term partnership, which will ultimately help both companies to grow and support the pharmaceutical industry in Israel,” he concluded.
